Nucleic Acid Sequencing for Gene Therapy Products: Methods, Testing Items, and Applications

Nucleic acid sequence determination is a cornerstone of quality control for gene therapy products, confirming the identity, integrity, and purity of plasmid DNA, viral vectors, mRNA therapeutics, and engineered cell constructs. Accredited third-party laboratories support gene therapy CMC programs with Sanger sequencing, next-generation sequencing (NGS), and long-read single-molecule platforms operated under ISO/IEC 17025 quality systems. This article outlines the sample types, testing items, analytical methods, and regulatory applications of nucleic acid sequencing in gene therapy development and manufacturing.

Technical Overview

Gene therapy products derive their therapeutic activity from defined nucleic acid sequences, including plasmid DNA, recombinant viral vector genomes (adeno-associated virus, lentivirus, adenovirus), mRNA molecules, and engineered transgenes introduced into patient cells. Because the nucleic acid payload is effectively the active pharmaceutical ingredient, regulatory authorities worldwide expect robust, sequence-based evidence that each batch matches its intended design. Nucleic acid sequence determination therefore serves as a fundamental identity, purity, and safety test throughout the product lifecycle, from vector design and cell bank characterization to final product release.

The principal objectives of sequencing in a gene therapy quality control program include:

• Confirmation that the product sequence is fully concordant with the designed reference sequence
• Detection of point mutations, insertions, deletions, recombination events, and truncated genomes
• Verification of critical structural elements such as inverted terminal repeats (ITRs), long terminal repeats (LTRs), promoters, enhancers, regulatory elements, and polyadenylation signals
• Assessment of vector genome integrity, heterogeneity, and packaging correctness
• Support for genetic stability studies, process comparability, and contamination investigations

Testing is typically performed by accredited third-party laboratories operating under ISO/IEC 17025-accredited quality management systems. Validated analytical procedures, controlled bioinformatics pipelines, data integrity practices aligned with ALCOA+ principles, and comprehensive reporting ensure that sequencing data are suitable for GMP decision-making and inclusion in regulatory submission packages.

Testing Samples

Plasmid DNA and Nucleic Acid Templates

This category includes research-grade and GMP-grade plasmids used as starting materials for viral vector or mRNA manufacturing, linearized DNA templates for in vitro transcription, intermediate samples from fermentation and purification, and reference standards. Sequencing confirms the complete plasmid backbone, the transgene insert, the origin of replication, and the selectable marker region.

Viral Vector Products

Samples include adeno-associated virus (AAV) drug substance and drug product, lentiviral and retroviral vectors with RNA genomes, adenoviral vectors, and herpesvirus-based vectors. In-process harvests, purified bulks, and final filled products can all be evaluated for vector genome identity, ITR integrity, and the presence of packaging impurities or partial genomes.

mRNA and Oligonucleotide Therapeutics

Synthetic mRNA, self-amplifying RNA, circular RNA, guide RNAs for gene editing, small interfering RNAs, and antisense oligonucleotides are sequenced to verify coding sequence fidelity, untranslated regions, poly(A) tail characteristics, and the absence of truncated or modified transcripts.

Gene-Edited and Engineered Cell Therapy Products

Chimeric antigen receptor T cells (CAR-T), TCR-engineered T cells, modified natural killer cells, and hematopoietic stem cell products are evaluated for transgene sequence integrity, vector integration site distribution, and clonal expansion monitoring in support of product characterization and safety assessment.

Cell Banks, Virus Banks, and Starting Materials

Bacterial master and working cell banks, producer cell lines such as HEK293 and insect cell lines used in baculovirus expression systems, helper plasmids, master and working virus banks, and research reagents are sequenced to establish genetic identity and to control the upstream supply chain.

Testing Items

A comprehensive gene therapy sequencing portfolio typically covers the following testing items, selected according to the modality, development stage, and regulatory strategy of the product:

• Full-length consensus sequence confirmation of plasmids, viral vector genomes, and transgenes
• AAV inverted terminal repeat (ITR) sequence and structural integrity verification
• Verification of regulatory elements, including promoters, enhancers, introns, post-transcriptional regulatory elements, and polyadenylation signals
• Low-frequency single nucleotide variant (SNV) and insertion-deletion (indel) detection
• Identification of recombination, rearrangement, truncation, and packaging impurities
• Vector genome completeness and population heterogeneity profiling
• Helper virus and packaging component sequence screening
• mRNA integrity assessment, including full-length coverage and poly(A) tail length distribution
• Vector integration site analysis and vector copy number support for integrating vectors
• Genetic stability evaluation across extended cell passages or virus generations
• Microbial identification by 16S rRNA and internal transcribed spacer (ITS) sequencing for contamination investigations
• Sequence-based support for comparability studies, stability programs, and reference standard qualification

Testing Methods

Sanger Sequencing

Capillary-based Sanger sequencing remains the reference method for consensus confirmation of clonal, homogeneous samples such as plasmid DNA. Primer walking strategies generate overlapping reads that are assembled into full-length coverage, with expert review of electropherograms to resolve ambiguities. The method delivers unambiguous, base-by-base confirmation ideal for batch release identity testing.

Short-Read Next-Generation Sequencing

Massively parallel short-read platforms enable whole-plasmid and whole-vector-genome sequencing with deep coverage. Variant calling algorithms can detect low-frequency mutations, typically down to approximately 0.1 to 1 percent depending on input quality and validation parameters. This approach is well suited to monitoring genome population heterogeneity and confirming the absence of emerging variants during manufacturing.

Long-Read Single-Molecule Sequencing

Single-molecule real-time (SMRT) and nanopore-based long-read technologies resolve regions that are difficult for short-read systems, including the complex secondary structures of AAV ITRs, structural rearrangements, full-length RNA transcripts, and poly(A) tail composition. Long reads also enable direct characterization of full vector genomes and packaged genome truncations without assembly ambiguity.

Targeted Deep Sequencing and RNA Sequencing

Amplicon-based deep sequencing provides high sensitivity at defined loci such as the transgene coding region or specific regulatory elements. Transcriptome and direct RNA sequencing approaches verify expressed sequences and RNA product integrity, supporting both characterization studies and formulation stability assessments.

Bioinformatics and Data Reporting

Validated bioinformatics pipelines perform reference-guided alignment, variant calling, coverage analysis, and quality control metric evaluation. Final reports include annotated concordance tables against the theoretical reference sequence, identified discrepancies with frequency estimates, coverage maps, and method parameters. All data handling complies with data integrity expectations, including audit trails, controlled storage, and independent review, consistent with ISO/IEC 17025 requirements and applicable national standards.

Applications

Sequencing data generated under controlled quality systems support gene therapy programs across discovery, development, manufacturing, and post-approval lifecycle stages. Typical applications include:

• Batch release and GMP quality control testing of drug substance and drug product
• Characterization of expression constructs, cell banks, and virus banks for regulatory filings
• Genetic stability demonstration across extended passaging and production scales
• Comparability assessment following process, site, or raw material changes
• Root-cause investigation of contamination, recombination, or unexpected potency results
• Support for investigational and marketing authorization submissions to global regulatory authorities
• Process development optimization and research-stage construct verification

Sponsors frequently outsource these activities to accredited third-party laboratories to access specialized platforms, validated workflows, and independent data, reducing burden on internal QC resources while strengthening the credibility of submission packages.

FAQ

What sample quantities are typically required?

Sanger sequencing generally requires several hundred nanograms to a few micrograms of plasmid DNA, or an equivalent of approximately ten to the eleventh power viral genomes for vector samples. NGS workflows often accommodate lower inputs, particularly with low-input library preparation protocols. Detailed requirements are confirmed case by case based on the sample type and selected method.

Can AAV inverted terminal repeats be fully verified?

Yes. ITRs form stable secondary structures and are refractory to standard short-read approaches. Specialized long-read strategies and tailored library preparation methods allow full-resolution confirmation of ITR sequence and structure, including detection of partial or truncated ITR species.

What variant detection sensitivity can be achieved?

With validated deep sequencing protocols, variants present at approximately 0.1 to 1 percent of the genome population can be reliably detected and reported, subject to input quality, library complexity, and validated analytical thresholds.

How long does testing take?

Sanger sequencing projects are commonly completed within three to seven working days. NGS and long-read projects typically require ten to twenty working days depending on scope, sample complexity, and reporting requirements. Project-specific timelines are provided during technical consultation.

Can sequencing results be used for GMP release and regulatory submissions?

Yes. Testing performed by accredited third-party laboratories under ISO/IEC 17025-compliant quality systems, with method validation, quality agreements, and complete documentation, generates data suitable for GMP batch disposition and inclusion in regulatory submission packages worldwide.

How is data integrity ensured?

Laboratory information management systems, electronic audit trails, controlled software environments, and dual data review ensure that all results are attributable, legible, contemporaneous, original, and accurate, in full alignment with current data integrity expectations.